Theracryf Future Growth

Future criteria checks 0/6

Theracryf's revenue is forecast to decline at 150.1% per annum while its annual earnings are expected to grow at 30.7% per year. EPS is expected to grow by 55.5% per annum. Return on equity is forecast to be -131.5% in 3 years.

Key information

30.7%

Earnings growth rate

55.5%

EPS growth rate

Biotechs earnings growth	43.1%
Revenue growth rate	-150.1%
Future return on equity	-131.5%
Analyst coverage	Low
Last updated	14 Jun 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8EV - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	N/A	-2	-2	-2	2
3/31/2025	N/A	-1	-1	-1	2
3/31/2024	0	-3	-3	-3	N/A
12/31/2023	1	-3	-3	-3	N/A
9/30/2023	1	-3	-4	-4	N/A
6/30/2023	1	-4	-4	-4	N/A
3/31/2023	0	-4	-4	-4	N/A
12/31/2022	0	-4	-4	-4	N/A
9/30/2022	N/A	-3	-3	-3	N/A
6/30/2022	N/A	-3	-3	-3	N/A
3/31/2022	N/A	-3	-3	-3	N/A
12/31/2021	N/A	-3	-3	-3	N/A
9/30/2021	N/A	-2	-3	-3	N/A
6/30/2021	0	-3	-3	-3	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	0	-3	-3	-3	N/A
9/30/2020	0	-3	-3	-3	N/A
6/30/2020	0	-3	-3	-3	N/A
3/31/2020	N/A	-3	-3	-3	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-2	-2	-2	N/A
6/30/2019	N/A	-3	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-3	-2	-2	N/A
12/31/2017	N/A	-3	N/A	-3	N/A
9/30/2017	N/A	-3	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-3	N/A
3/31/2017	N/A	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-4	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	N/A	-3	N/A	-2	N/A
12/31/2015	N/A	-3	N/A	-1	N/A
9/30/2015	N/A	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A
3/31/2015	N/A	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8EV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8EV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8EV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8EV is forecast to have no revenue next year.

High Growth Revenue: 8EV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 8EV is forecast to be unprofitable in 3 years.

Theracryf Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Theracryf Plc to Report First Half, 2025 Results on Nov 28, 2024

Less than half of directors are independent

Theracryf Plc Announces Demise of Sue Foden, Chair

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

New major risk - Shareholder dilution

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

New major risk - Revenue and earnings growth

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies